tiprankstipranks
Advertisement
Advertisement

CRSP Stock Latest News

Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
The FlyCrispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
20d ago
CRSP
Crispr Therapeutics price target lowered to $82 from $83 at BofA
PremiumThe Fly
Crispr Therapeutics price target lowered to $82 from $83 at BofA
20d ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
20d ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
PremiumRatings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
22d ago
CRSP
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
PremiumRatings
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
22d ago
CRSP
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
PremiumRatingsCrispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
22d ago
CRSP
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
Premium
Ratings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
22d ago
CRSP
Citi ups Crispr Therapeutics target on Casgvey momentum
Premium
The Fly
Citi ups Crispr Therapeutics target on Casgvey momentum
22d ago
CRSP
Crispr Therapeutics price target raised to $88 from $82 at Citi
PremiumThe Fly
Crispr Therapeutics price target raised to $88 from $82 at Citi
23d ago
CRSP
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
PremiumThe Fly
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
23d ago
CRSP
Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial
PremiumCompany Announcements
Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial
1M ago
CRSP
Crispr Therapeutics AG Slides Despite Bullish Wall Street
PremiumWeekend Updates
Crispr Therapeutics AG Slides Despite Bullish Wall Street
2M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
PremiumRatingsCRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
2M ago
CRSP
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
Premium
Ratings
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
2M ago
CRSP
Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts
Premium
Weekend Updates
Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts
2M ago
NTR
ADMA
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
PremiumThe Fly
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
3M ago
GS
TP
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
PremiumThe Fly
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
3M ago
CRSP
Shareholders Approve New Incentive Plan and Governance Measures
PremiumCompany Announcements
Shareholders Approve New Incentive Plan and Governance Measures
3M ago
8K
CRSP
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
3M ago
AZN
BMY
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
PremiumCompany AnnouncementsCrispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
3M ago
CRSP
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
Premium
The Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
4M ago
CRSP
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
4M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >